Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cytarabine + SKI-G-801|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cytarabine||Cytosar-U||Ara-C||Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).|
|SKI-G-801||FLT3 kinase inhibitor SKI G-801|SKI G-801|G-801|G-749 HCl||Aurkb Inhibitors 20 Aurkc Inhibitors 3 AXL Inhibitor 29 FGFR1 Inhibitor 27 FGFR3 Inhibitor 19 FLT3 Inhibitor 61 MERTK Inhibitor 13 RET Inhibitor 48 VEGFR1 Inhibitor 5||SKI-G-801 is a multi-kinase inhibitor that has activity against wild-type and mutant forms of FLT3, which blocks FLT3 signaling and potentially inhibits proliferation of FLT3-overexpressing tumor cells, and has additional activity against AXL, potentially leading to decreased tumor cell metastasis, as well as MER, RET, VEGFR1, FMS, FGFR1, FGFR3, AURKB, and AURKC (NCI Drug Dictionary; Cancer Res 2019;79(13 Suppl):Abstract nr 2010).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins||acute myeloid leukemia||sensitive||Cytarabine + SKI-G-801||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of SKI-G-801 and Cytosar-U (cytarabine) resulted in a synergistic effect, demonstrating greater inhibition of proliferation compared to G-749 alone in acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (PMID: 24532805).||24532805|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|